Turning novel biology into first-in-class cancer therapeutics.
At Vivace Therapeutics, we pursue our work with passion, driven by a conviction to help people fight cancer and live life to the fullest.
Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company adopting a capital-efficient approach to bring novel therapies to patients in need. Our experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that we believe can help conquer cancer.
Sofie Qiao, Ph.D.
President and Chief Executive Officer
Leonard Post, Ph.D.
Chief Scientific Officer
Hippo-YAP Signaling Pathway
Vivace Therapeutics has discovered, and is now developing, multiple novel small-molecule medicines targeting the Hippo-YAP pathway, which has shown to be involved in the regulation of cell proliferation, programmed cell death and cell migration. The effector of the pathway is the YAP – TEAD transcription complex.
In healthy conditions, this pathway controls tissue regeneration and the size and shape of organs. However, mutations of the Hippo – YAP pathway can be oncogenic and be the dominant driver for several forms of cancer including mesothelioma, meningioma, and schwannoma. Additionally, dysfunction of the Hippo – YAP pathway contributes to a wide range of cancers including lung, gastric, colon, cervical, ovarian, breast, melanoma, hepatocellular carcinoma and squamous cell carcinoma. YAP hyperactivity is also linked to resistance to targeted therapies, cancer relapse and worse outcomes for patients.
With an industry-leading understanding of the Hippo – YAP pathway’s complex biology, Vivace is bringing forth a new generation of cancer therapeutics in the form of YAP-TEAD transcription activity inhibitors.
“(A,B) Scanning electron micrographs of (A) a wild-type fly and (B) a fly with clones of cells homozygous mutant for hippo that exhibit overgrowth of the adult cuticle (Udan et al., 2003).”
Building upon the biology of the Hippo-YAP Pathway, YAP – TEAD inhibitors could also have broad implications in non-oncology indications such as fibrotic disease.
Publications and Presentations
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer
Ma et al. Nature Communications. 2022;13
Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
Tang et al. Mol Cancer Ther. 2021;20(6):986–998
The Hippo Pathway: Biology and Pathophysiology
Ma et al. Annual Reviews. 2018;88:577-604.
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
Yu et al. Cell. 2015;163(4):811-28.
The Hippo Pathway and Human Cancer
Harvey et al. Nat Rev Cancer. 2013;13(4):246-57.
The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models
Tracy T. Tang and Leonard Post, Vivace Therapeutics, 2022
Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022
Vivace Therapeutics has a proven track record of leveraging the best people and science in the United States and China.
1500 Fashion Island Blvd.
San Mateo, California 94404